Increasing evidence has shown that STAMBP is highly elevated and is linked to poor clinical prognosis in multiple cancers, such as lung adenocarcinoma, breast cancer, triple-negative breast cancer, and PC [19, 20, 22]. Here, STAMBP is linked to triple-negative breast carcinoma.